Homozygous deletion ofCDKN2Aby fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas

被引:30
作者
Marker, Daniel F. [1 ]
Pearce, Thomas M. [1 ]
机构
[1] Univ Pittsburgh, Dept Pathol, Div Neuropathol, Med Ctr, S701 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA
关键词
CDKN2A; IDH; Astrocytoma; FISH; DIFFUSE; SURVIVAL;
D O I
10.1186/s40478-020-01044-y
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
IDH-mutant astrocytomas have a more indolent natural history and better prognosis than their IDH-wild type counterparts, but are still graded according to schemes developed prior to the recognition of this type of neoplasm as a distinct entity. Homozygous deletion ofCDKN2Ahas been proposed as a molecular correlate of aggressive behavior in these tumors, and may be incorporated into future grading systems in an effort to improve prognostic stratification. Fluorescence in situ hybridization (FISH) is a common ancillary testing modality used to assessCDKN2Astatus, but the specifics of how to best interpret FISH results for prognostication of gliomas have not been clearly defined in the literature. To address this issue, we performed a retrospective analysis of prospectively collectedCDKN2AFISH data from 108 primary and 43 recurrent IDH-mutant astrocytomas diagnosed between 2007-2020 at the University of Pittsburgh Medical Center. High levelCDKN2Ahomozygous deletion was rare in primary tumors and was identified more frequently in recurrent tumors. Multivariate Cox Proportional-Hazards analysis demonstrated that histologic grade andCDKN2Astatus are independent predictors of survival, and the prognostic value ofCDKN2Ais maximized by applying a threshold of >= 30% of tumor cells with homozygous deletion by FISH to define a positive result. At this threshold,CDKN2Adeletion significantly stratified survival of histologic grade 4 tumors, but grade 2 and 3 tumors rarely exceeded this cutoff value and did not show worse survival. Lower thresholds identified additional lower grade tumors, but were not prognostically useful. Compared to prior studies, the lack of prognostic significance ofCDKN2Ahomozygous deletion by FISH in grade 2-3 IDH-mutant astrocytomas may reflect differences in cohort populations or technical differences between testing modalities. Definitive criteria for determiningCDKN2Ahomozygous deletion by various methodologies will be critical if this is to be included in future grading schemes.
引用
收藏
页数:12
相关论文
共 15 条
[1]  
Alghamri MS., 2020, NEUROONCOL ADV, V2
[2]   Prognostic relevance of genetic alterations in diffuse lower-grade gliomas [J].
Aoki, Kosuke ;
Nakamura, Hideo ;
Suzuki, Hiromichi ;
Matsuo, Keitaro ;
Kataoka, Keisuke ;
Shimamura, Teppei ;
Motomura, Kazuya ;
Ohka, Fumiharu ;
Shiina, Satoshi ;
Yamamoto, Takashi ;
Nagata, Yasunobu ;
Yoshizato, Tetsuichi ;
Mizoguchi, Masahiro ;
Abe, Tatsuya ;
Momii, Yasutomo ;
Muragaki, Yoshihiro ;
Watanabe, Reiko ;
Ito, Ichiro ;
Sanada, Masashi ;
Yajima, Hironori ;
Morita, Naoya ;
Takeuchi, Ichiro ;
Miyano, Satoru ;
Wakabayashi, Toshihiko ;
Ogawa, Seishi ;
Natsume, Atsushi .
NEURO-ONCOLOGY, 2018, 20 (01) :66-77
[3]   CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas [J].
Appay, Romain ;
Dehais, Caroline ;
Maurage, Claude-Alain ;
Alentorn, Agusti ;
Carpentier, Catherine ;
Colin, Carole ;
Ducray, Francois ;
Escande, Fabienne ;
Idbaih, Ahmed ;
Kamoun, Aurelie ;
Marie, Yannick ;
Mokhtari, Karima ;
Tabouret, Emeline ;
Trabelsi, Nesrine ;
Uro-Coste, Emmanuelle ;
Delattre, Jean-Yves ;
Figarella-Branger, Dominique ;
Desenclos, C. ;
Sevestre, H. ;
Menei, P. ;
Rousseau, A. ;
Cruel, T. ;
Lopez, S. ;
Mihai, M-I. ;
Petit, A. ;
Adam, C. ;
Parker, F. ;
Dam-Hieu, P. ;
Quintin-Roue, I. ;
Eimer, S. ;
Loiseau, H. ;
Bekaert, L. ;
Chapon, F. ;
Ricard, D. ;
Godfraind, C. ;
Khallil, T. ;
Cazals-Hatem, D. ;
Faillot, T. ;
Gaultier, C. ;
Tortel, M. C. ;
Carpiuc, I. ;
Richard, P. ;
Lahiani, W. ;
Aubriot-Lorton, H. ;
Ghiringhelli, F. ;
Maurage, C. A. ;
Ramirez, C. ;
Gueye, E. M. ;
Labrousse, F. ;
Chinot, O. .
NEURO-ONCOLOGY, 2019, 21 (12) :1519-1528
[4]   cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas [J].
Brat, Daniel J. ;
Aldape, Kenneth ;
Colman, Howard ;
Figrarella-Branger, Dominique ;
Fuller, Gregory N. ;
Giannini, Caterina ;
Holland, Eric C. ;
Jenkins, Robert B. ;
Kleinschmidt-DeMasters, Bette ;
Komori, Takashi ;
Kros, Johan M. ;
Louis, David N. ;
McLean, Catriona ;
Perry, Arie ;
Reifenberger, Guido ;
Sarkar, Chitra ;
Stupp, Roger ;
van den Bent, Martin J. ;
von Deimling, Andreas ;
Weller, Michael .
ACTA NEUROPATHOLOGICA, 2020, 139 (03) :603-608
[5]   Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma [J].
Ceccarelli, Michele ;
Barthel, Floris P. ;
Malta, Tathiane M. ;
Sabedot, Thais S. ;
Salama, Sofie R. ;
Murray, Bradley A. ;
Morozova, Olena ;
Newton, Yulia ;
Radenbaugh, Amie ;
Pagnotta, Stefano M. ;
Anjum, Samreen ;
Wang, Jiguang ;
Manyam, Ganiraju ;
Zoppoli, Pietro ;
Ling, Shiyun ;
Rao, Arjun A. ;
Grifford, Mia ;
Cherniack, Andrew D. ;
Zhang, Hailei ;
Poisson, Laila ;
Carlotti, Carlos Gilberto, Jr. ;
Tirapelli, Daniela Pretti da Cunha ;
Rao, Arvind ;
Mikkelsen, Tom ;
Lau, Ching C. ;
Yung, W. K. Alfred ;
Rabadan, Raul ;
Huse, Jason ;
Brat, Daniel J. ;
Lehman, Norman L. ;
Barnholtz-Sloan, Jill S. ;
Zheng, Siyuan ;
Hess, Kenneth ;
Rao, Ganesh ;
Meyerson, Matthew ;
Beroukhim, Rameen ;
Cooper, Lee ;
Akbani, Rehan ;
Wrensch, Margaret ;
Haussler, David ;
Aldape, Kenneth D. ;
Laird, Peter W. ;
Gutmann, David H. ;
Noushmehr, Houtan ;
Iavarone, Antonio ;
Verhaak, Roel G. W. .
CELL, 2016, 164 (03) :550-563
[6]   Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas [J].
Chiosea, Simion ;
Krasinskas, Alyssa ;
Cagle, Philip T. ;
Mitchell, Kisha A. ;
Zander, Dani S. ;
Dacic, Sanja .
MODERN PATHOLOGY, 2008, 21 (06) :742-747
[7]   Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas [J].
Cimino, Patrick J. ;
Holland, Eric C. .
NEURO-ONCOLOGY, 2019, 21 (06) :819-821
[8]  
Gabriel, 2020, ZENODO
[9]   Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas [J].
Horbinski, Craig ;
Nikiforova, Marina N. ;
Hagenkord, Jill M. ;
Hamilton, Ronald L. ;
Pollack, Ian F. .
NEURO-ONCOLOGY, 2012, 14 (06) :777-789
[10]   cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading [J].
Louis, David N. ;
Wesseling, Pieter ;
Aldape, Kenneth ;
Brat, Daniel J. ;
Capper, David ;
Cree, Ian A. ;
Eberhart, Charles ;
Figarella-Branger, Dominique ;
Fouladi, Maryam ;
Fuller, Gregory N. ;
Giannini, Caterina ;
Haberler, Christine ;
Hawkins, Cynthia ;
Komori, Takashi ;
Kros, Johan M. ;
Ng, H. K. ;
Orr, Brent A. ;
Park, Sung-Hye ;
Paulus, Werner ;
Perry, Arie ;
Pietsch, Torsten ;
Reifenberger, Guido ;
Rosenblum, Marc ;
Rous, Brian ;
Sahm, Felix ;
Sarkar, Chitra ;
Solomon, David A. ;
Tabori, Uri ;
van den Bent, Martin J. ;
von Deimling, Andreas ;
Weller, Michael ;
White, Valerie A. ;
Ellison, David W. .
BRAIN PATHOLOGY, 2020, 30 (04) :844-856